2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc.(NasdaqGS:TSVT.V) operates independently of bluebird bio, Inc. as of November 4, 2021.
IPO Year:
Exchange: NASDAQ
Website: 2seventybio.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/6/2024 | $5.00 → $2.00 | Neutral → Sell | Goldman |
1/31/2024 | Outperform → Market Perform | TD Cowen | |
1/31/2024 | $5.00 → $18.00 | Market Perform → Outperform | Leerink Partners |
10/30/2023 | $6.00 | Outperform → Market Perform | Leerink Partners |
10/12/2023 | $13.00 | Buy | Citigroup |
9/13/2023 | $5.00 | Buy → Neutral | Goldman |
9/12/2023 | Buy → Neutral | Guggenheim | |
7/28/2023 | $25.00 → $13.00 | Overweight → Equal-Weight | Morgan Stanley |
10/31/2022 | $30.00 | Buy | Guggenheim |
5/2/2022 | $26.00 | Buy | Goldman |
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
2seventy bio, Inc. (NASDAQ:TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 12:20 p.m. ET in New York. A live webcast of the fireside chat will be available via the Investors and Media section of the company's website at https://ir.2seventybio.com. Replays will be archived on the 2seventy bio website for 30 days following the events. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to
Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on Abecma with streamlined cost structure Approximately $28 million (43%) quarter-on-quarter reduction in operating expenses due to completion of sale of R&D business to Regeneron on April 1, 2024 Ended quarter with approximately $202 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today re
2seventy bio, Inc. (NASDAQ:TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event's start. A replay of the call will be available on the 2seventy bio website following the completion of the call. About 2seventy bio Our name, 2seventy
- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc. (NASDAQ:TSVT), announced today the completion of an asset purchase agreement ("APA") by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. The program is based on the original research agreement, established in 2019, which focused on
2seventy bio, Inc. (NASDAQ:TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA in a virtual fireside chat on Tuesday, May 28, 2024 at 8:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL, on Monday, June 10, 2024 at 8:40 a.m. ET Live webcasts of the fireside chats will be available via the Investors and Media section of the company's website at https://ir.2seventybio.com. Replays will be archived on the 2seventy bio website for 30 days following the events. About 2seventy bio Our name, 2seventy bio, reflects w
U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets Company on Track to Focus Exclusively on Development and Commercialization of Abecma with Streamlined Cost Structure Abecma generated $52 million U.S. commercial revenue in the first quarter of 2024 Ended quarter with $181.4 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024.
2seventy bio, Inc. (NASDAQ:TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event's start. A replay of the call will be available on the 2seventy bio website following the completion of the call. About 2seventy bio Our name, 2seventy bi
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more patients with relapsed or refractory multiple myeloma earlier in their treatment journey as a one-time infusion offering meaningful treatment-free intervals when responding to therapy Abecma is now approved in the U.S., Japan, Switzerland and the EU for earlier use for triple-class exposed relapsed and/or refractory multiple myeloma, underscoring BMS' commitment to delivering Abecma globally, with consistently high manuf
- Company Now Exclusively Focused on Development and Commercialization of Abecma - 2seventy bio, Inc. (NASDAQ:TSVT), announced today the completion of the asset purchase agreement ("APA") by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business. Going forward, 2seventy bio will focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb
2seventy bio, Inc. (NASDAQ:TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the "Board"), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. "We are pleased to welcome Eli and Charlie to the 2seventy Board," said Dan Lynch, chair of the Board of Directors. "Eli is a highly regarded, leading life sciences and healthcare investor and has a deep understanding of and history with the Company. Charlie has a track record of helping compan
10-Q - 2seventy bio, Inc. (0001860782) (Filer)
8-K - 2seventy bio, Inc. (0001860782) (Filer)
8-K - 2seventy bio, Inc. (0001860782) (Filer)
8-K - 2seventy bio, Inc. (0001860782) (Filer)
8-K - 2seventy bio, Inc. (0001860782) (Filer)
10-Q - 2seventy bio, Inc. (0001860782) (Filer)
8-K - 2seventy bio, Inc. (0001860782) (Filer)
ARS - 2seventy bio, Inc. (0001860782) (Filer)
DEFA14A - 2seventy bio, Inc. (0001860782) (Filer)
DEF 14A - 2seventy bio, Inc. (0001860782) (Filer)
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO). Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. Related: FDA Approves Bristol-Myers/2seventy Bio’s Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer. The program is based on the original research a
Wedbush analyst David Nierengarten reiterates 2seventy bio (NASDAQ:TSVT) with a Neutral and maintains $5 price target.
- Divestiture Supports Company Focus on Development and Commercialization of Abecma-
Canaccord Genuity analyst John Newman maintains 2seventy bio (NASDAQ:TSVT) with a Buy and lowers the price target from $12 to $11.
2seventy bio (NASDAQ:TSVT) reported quarterly losses of $(0.81) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(1.08) per share from the same period last year. The company reported quarterly sales of $12.44 million which missed the analyst consensus estimate of $14.08 million by 11.68 percent. This is a 70.12 percent decrease over sales of $41.62 million the same period last year.
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-related caution for medications—for all chimeric antigen receptor (CAR) T-cell therapies. According to the agency, these blood cancer treatments may pose a risk of secondary cancers. The health regulator has required related updates to other label sections, such as warnings and precautions, postmarketing experience, patient counseling information, and medication guides. The agency said patients and clinical trial participants receiving treatment with these products should be monitored lifelong for secondary malignancies and notify the manu
Citigroup analyst Samantha Semenkow maintains 2seventy bio (NASDAQ:TSVT) with a Buy and raises the price target from $9 to $12.
Friday, the FDA approved Bristol-Myers Squibb Company (NYSE:BMY) and 2seventy Bio Inc’s (NASDAQ:TSVT) Abecma (idecabtagene vicleucel; ide-cel) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy. The approval is based on results from the KarMMa-3 trial that showed Abecma helped extend the time before disease progression by 13.3 months on average in patients whose cancer has returned or stopped responding to at least two prior treatments compared to 4.4 months progression-free survival seen in trial patients who received standard of care. This approval expands Abecma’s indication, making it available in earlier lines to patients who
Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on Abecma with streamlined cost structure Approximately $28 million (43%) quarter-on-quarter reduction in operating expenses due to completion of sale of R&D business to Regeneron on April 1, 2024 Ended quarter with approximately $202 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today re
2seventy bio, Inc. (NASDAQ:TSVT) will announce its second quarter 2024 financial results on Wednesday, August 7, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event's start. A replay of the call will be available on the 2seventy bio website following the completion of the call. About 2seventy bio Our name, 2seventy
U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets Company on Track to Focus Exclusively on Development and Commercialization of Abecma with Streamlined Cost Structure Abecma generated $52 million U.S. commercial revenue in the first quarter of 2024 Ended quarter with $181.4 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024.
2seventy bio, Inc. (NASDAQ:TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event's start. A replay of the call will be available on the 2seventy bio website following the completion of the call. About 2seventy bio Our name, 2seventy bi
New strategic path forward as Abecma-focused company announced in January 2024; on track to close Asset Sale of R&D pipeline to Regeneron in the first half of 2024 U.S. Food and Drug Administration Oncologic Drugs Advisory Committee scheduled for March 15, 2024, to review data supporting the supplemental Biologics License Application for Abecma® (idecabtagene vicleucel) for triple-class exposed relapsed or refractory multiple myeloma Abecma generated $56 million U.S. commercial revenue in the fourth quarter of 2023 and $358 million for the full year, shared equally with Bristol Myers Squibb Ended quarter with $221.8 million cash, cash equivalents, and marketable securities; cash runwa
2seventy bio, Inc. (NASDAQ:TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management team will also be presenting at the following upcoming investor conferences: TD Cowen 44th Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2024 at 2:10 p.m. ET Leerink Partners Global Biopharma Conference in Miami, FL on Wednesday, March 13 at 8:00 a.m. ET Live webcasts of the investor conference presentations will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. Replays will be archived on 2s
- Company to focus exclusively on commercialization and development of Abecma, in partnership with Bristol Myers Squibb - - Company to sell R&D pipeline to Regeneron to launch Regeneron Cell Medicines business led by 2seventy bio's Chief Scientific Officer, Philip Gregory - Chip Baird named incoming Chief Executive Officer; Nick Leschly named incoming Chairman of Board of Directors - - Expected annual cost savings of approximately $150 million in 2024 and $200 million in 2025; cash runway extended beyond 2027 - - Conference call to be held today at 8:00 a.m. ET - 2seventy bio, Inc. (NASDAQ:TSVT), announced today that it is transforming the Company to focus exclusively on the commercializ
2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. A replay of the call will be available on the 2seventy bio website for 30 days following the event. ASH Presentation Details Oral Presentation: Idecabtagene Vicl
Abecma (idecabtagene vicleucel) data to be presented at ASH 2023; multiple new analyses of KarMMa-3 and KarMMa-2c add to growing body of data supporting the potential safety and efficacy of Abecma in earlier lines of treatment Abecma generated $69 million U.S. commercial revenue in the third quarter of 2023; $302 million U.S. commercial revenue year-to-date Two solid tumor programs positioned to enter clinical trials in 2024 Ended quarter with $284.3 million cash, cash equivalents, and marketable securities Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for
2seventy bio, Inc. (NASDAQ:TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It's recommended that participants join 10 minutes prior to the event's start. A replay of the call will be avail
2seventy bio, Inc. (NASDAQ:TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the "Board"), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. "We are pleased to welcome Eli and Charlie to the 2seventy Board," said Dan Lynch, chair of the Board of Directors. "Eli is a highly regarded, leading life sciences and healthcare investor and has a deep understanding of and history with the Company. Charlie has a track record of helping compan
Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh
O'Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated biopharmaceutical company Founder and current CEO Brendan Frey, Ph.D., F.R.S.C. to assume new role of chief innovation officer, remain a member of the board and bolster plans for further technology development and innovation, leveraging artificial intelligence (AI) to decode RNA biology for novel drug development Lead independent director Chip Baird appointed as chair of the board Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines
2seventy bio, Inc. (NASDAQ:TSVT) today announced the appointment of Wei Lin, M.D. to the company's Board of Directors, effective immediately. "We are thrilled to welcome Dr. Wei Lin to 2seventy's Board during an exciting time in our Company's growth," said Nick Leschly, chief kairos officer. "Wei's leadership and deep expertise in clinical development strategy for cancer immunotherapy programs will be invaluable as we innovate new treatments to provide more time to patients and families living with cancer." "I am excited to join 2seventy's Board of Directors and contribute my experience in clinical development," said Wei Lin, M.D. "Unleashing the power of the T cell is a truly inspiring s
CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announced the appointment of Kevin Chin, M.D., M.S., as Chief Medical Officer. Dr. Chin is a seasoned oncology clinical development expert in T cell directed immunotherapies with a proven track record of developing successful programs from research to regulatory approvals. In his role, Dr. Chin will be responsible for the progress of the company's clinical portfolio starting with the recently announced START-001 Phase 1/2 clinical trial of Marengo's immuno-oncol
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. "I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and build our commercial capabilities to support the launch of this initial product and future next-gen cell therapies within our MAGE-A4 franchise. Her fresh perspective and leadership abilities will supp
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
Goldman downgraded 2seventy bio from Neutral to Sell and set a new price target of $2.00 from $5.00 previously
TD Cowen downgraded 2seventy bio from Outperform to Market Perform
Leerink Partners upgraded 2seventy bio from Market Perform to Outperform and set a new price target of $18.00 from $5.00 previously
Leerink Partners downgraded 2seventy bio from Outperform to Market Perform and set a new price target of $6.00
Citigroup initiated coverage of 2seventy bio with a rating of Buy and set a new price target of $13.00
Goldman downgraded 2seventy bio from Buy to Neutral and set a new price target of $5.00
Guggenheim downgraded 2seventy bio from Buy to Neutral
Morgan Stanley downgraded 2seventy bio from Overweight to Equal-Weight and set a new price target of $13.00 from $25.00 previously
Guggenheim initiated coverage of 2seventy bio with a rating of Buy and set a new price target of $30.00
Goldman initiated coverage of 2seventy bio with a rating of Buy and set a new price target of $26.00